Oppenheimer analyst Suraj Kalia maintained a Hold rating on Nevro Crop (NVRO) today. The company’s shares closed last Tuesday at $99.98.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 2.4% and a 50.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Edwards Lifesciences.
Nevro Crop has an analyst consensus of Strong Buy, with a price target consensus of $140.71.
See today’s analyst top recommended stocks >>
The company has a one-year high of $148.06 and a one-year low of $54.00. Currently, Nevro Crop has an average volume of 521.8K.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVRO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
